NICE Board says new method allowing greater weight to be given to severe diseases is working
At today's meeting (25th September 2024) our board has concluded that the new severity modifier is working as intended.
Our recommendations help practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
At today's meeting (25th September 2024) our board has concluded that the new severity modifier is working as intended.
Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins.
Learn more about our independent advisory committees and how you can get involved.
Today (1 October 2024) NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of advanced breast cancer.
Best practice resources for practitioners and commissioners.
Useful sources of information and advice for healthcare professionals, patients, parents and carers.
Summaries of evidence and advice on common health topics (CKS)
Independent committees develop and update our guidance. Join a NICE committee and use your voice to drive forward critical discussions - turning your personal experiences into guidance that benefits millions of people.
As a NICE committee member, you'll play a vital role in shaping our work. Your insights help equip health and care practitioners with the guidance they need to deliver best practice care.